| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e86b3c104eca1835e94724dc8ac53e44 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2016-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95f2f2b5fa8e9f8a7674a3d9ab4b154f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16f8f116f74cd11f6a512277de2ee3c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eb14ade654260fbe9f9f6e869f7a5bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b762c467ecbcb54f1a9107dd8a71bade |
| publicationDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017079753-A |
| titleOfInvention |
Administration plan for administering CD19xCD3 bispecific antibody |
| abstract |
A method for assessing (analyzing) the risk of a potential adverse reaction for a patient mediated by administration of a CD19xCD3 bispecific antibody to a human patient to effectively attack antibody-based cancer cells. And providing a dosing regimen of CD19xCD3 bispecific antibodies. An evaluation method comprising the step of measuring the ratio of B cells to T cells of a patient, wherein a ratio of about 1: 5 or less is an indicator for the risk of a potential adverse reaction for the patient. A method (administration schedule) for administering a CD19xCD3 bispecific antibody to a human patient having a B: T cell ratio of about 1: 5 or less, comprising: (a) administering a first dose of antibody in a first period Administering, followed by (b) administering a second dose of antibody in a second period, wherein the second dose is greater than the first dose. A method of further administering a third dose of antibody in the third period. [Selection figure] None |
| priorityDate |
2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |